公开(公告)号：US09623098B2

公开(公告)日：2017-04-18

申请号：US12993693

申请日：2009-05-26

申请人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

发明人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

IPC分类号： A61K39/015 ,  A61K39/12 ,  A61K39/165 ,  A61K39/00

CPC分类号： A61K39/015 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5256 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2760/18434 ,  C12N2760/18443

摘要： The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost.

公开(公告)号：US20120121538A1

公开(公告)日：2012-05-17

申请号：US13318701

申请日：2010-05-03

申请人： Reinhard Glueck ,  Agata Fazzio ,  Viviana Gianino ,  Martin A. Billeter

发明人： Reinhard Glueck ,  Agata Fazzio ,  Viviana Gianino ,  Martin A. Billeter

IPC分类号： A61K39/165 ,  A61K38/20 ,  A61P31/14 ,  A61K39/295 ,  C12N15/63 ,  C12N1/21 ,  C12N5/10 ,  A61P37/04 ,  A61P33/06

CPC分类号： A61K39/165 ,  A61K35/13 ,  A61K38/2013 ,  A61K39/0015 ,  A61K39/015 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/575 ,  A61K2039/70 ,  C12N7/00 ,  C12N2760/18421 ,  C12N2760/18434 ,  C12N2760/18442 ,  C12N2760/18443 ,  Y02A50/412

摘要： A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.

摘要翻译： 描述了包含编码几种恶性疟原虫抗原的异源核酸的包含不同的减毒重组麻疹 - 疟疾载体的麻疹 - 疟疾综合疫苗。 优选地，其涉及包含编码恶性疟原虫的环子孢子（CS）蛋白，恶性疟原虫的裂殖子表面蛋白1（MSP-1）及其衍生物（p-42; p-83- 30-38）以其糖基化和分泌形式，以及恶性疟原虫的顶端膜抗原1（AMA1）以其锚定或分泌形式。 病毒载体源自减毒的麻疹病毒，其基于用作疫苗的菌株，并且有效地传递感兴趣的基因并且有效地结合并感染相关的免疫细胞。

公开(公告)号：US20110129493A1

公开(公告)日：2011-06-02

申请号：US12993693

申请日：2009-05-26

申请人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

发明人： Sanjeev K. Mendiretta ,  Reinhard Glueck ,  Viviana Giannino ,  Giuseppina Cantarella ,  Francesca Scuderi ,  Martin Billeter ,  Agata Fazzio

IPC分类号： A61K39/295 ,  C12N15/63 ,  A61P31/14 ,  A61P31/20 ,  C12N5/10 ,  C12N1/21

CPC分类号： A61K39/015 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5256 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2760/18434 ,  C12N2760/18443

摘要： The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost.

摘要翻译： 本发明涉及针对麻疹和人乳头状瘤病毒（HPV）的组合疫苗。 特别地，本发明涉及包含编码由HPV衍生的单个或几个抗原的异源核酸的重组麻疹病毒载体，优选主要的capside抗原L1，次要的抗原L2，早期基因E6和HPV的早期基因E7癌蛋白 16型，以及任选的类型18,6和11.在第一个实施方案中，产生表达HPV抗原，优选L1和/或L2的预防性疫苗，使得它们在哺乳动物，优选人类中诱导有效的长效免疫应答 防止HPV和MV感染。 在另一个实施方案中，生成表达E6和E7蛋白以及任选的L1和L2的治疗性疫苗，使得它们诱导强的免疫应答将解决包括HPV诱导的宫颈癌在早期或晚期的持续性HPV感染。 在优选的实施方案中，组合的疫苗易于大规模生产并且可以以低成本分布。